Home » Vyriad, Imanis Ink Cancer Companion Dx Development Deal

Vyriad, Imanis Ink Cancer Companion Dx Development Deal

Aug 16, 2016
|
staff reporter

NEW YORK (GenomeWeb) – Vyriad announced today that it has partnered with Imanis Life Sciences to develop in vitro and in vivo tests to predict a patient's likelihood of responding to its oncolytic virus therapeutics.

Vyriad is developing cancer treatments that use vesicular stomatitis and measles viruses modified with genes encoding known tumor antigens in order to trigger anticancer immune responses.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Scan

The Apple's Journey

The apple has traveled westward and eastward along the Silk Road, according to a new genetic analysis.

This Week in Nature

In Nature this week: GWAS data used to reposition drugs for psychiatric use, and more.

Change Is Hard to Do

Genetic disease risk information doesn't always spur people to make healthy lifestyle changes, according to the Associated Press.

Possible Paths for CUP

A University of California, San Diego-led team has used liquid biopsies to uncover possible treatments for patients with cancers of unknown primary.

What's Popular?

In Molecular Diagnostics

  1. ASCO Updates NSCLC Guidelines With New Directives for Genomic Testing

  2. Dutch Researchers Develop ThromboSeq Test to Detect Lung Cancer

  3. Color Raises $52M of Planned $80M Financing

  4. Biocept, UT Southwestern Partner for ALK Liquid Biopsy Study

  5. Cynvenio, St. Luke's Partner on Breast Cancer Study

Sponsorships

Privacy Policy.  Copyright © 2017 GenomeWeb LLC.  All Rights Reserved.